Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome...

This week’s clinical update looks at a Phase 1/2 trial for a CRISPR-edited checkpoint cell therapy for difficult-to-treat gastrointestinal cancers...

This week’s clinical update looks at a Phase 1/2 trial for VOR33, a CRISPR-Cas9-edited haematopoietic stem and progenitor cell (HSPC) therapy under...

This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...

In this week’s update, we present a CRISPR-based therapy for sickle cell disease (SCD) that has moved from the investigational new drug (IND) stage...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

This week’s update looks at a CRISPR-edited CAR T-cell therapy in clinical development for the treatment of a range of B cell cancers.

This week’s update looks at a combined vaccine/CRISPR-edited T cell trial for prostate cancer, and a CRISPR-edited CAR-T cell trial for non-small cell...